Research & Development
Media & Press
Active surveillance on the rise for low-risk prostate cancer
Week in Review: Natera nabs commercial coverage | U.S. government’s mRNA vaccine investment | Could Medicare have saved millions on drug testing payments?
Electronic health record interventions reduce unnecessary urine culture orders, study finds
Sophia Genetics, Qiagen collaborate on next-generation sequencing for tumor analysis
Natera receives commercial payor coverage for molecular residual disease test
Page 1 of 1